Radiopharm Theranostics Ltd (RAD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Radiopharm Theranostics Ltd (RAD) has a cash flow conversion efficiency ratio of -0.454x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-22.67 Million ≈ $-16.04 Million USD) by net assets (AU$49.94 Million ≈ $35.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Radiopharm Theranostics Ltd to measure how many days the company can operate on defensive assets alone.
Radiopharm Theranostics Ltd - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Radiopharm Theranostics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Radiopharm Theranostics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Radiopharm Theranostics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Power Solution Technologies Public Company Limited
BK:PSTC
|
-0.010x |
|
Dongyang Piston Co Ltd
KO:092780
|
-0.106x |
|
Maven Wireless Sweden AB
ST:MAVEN
|
-0.062x |
|
Verde Clean Fuels Inc.
NASDAQ:VGAS
|
-0.046x |
|
Laser Photonics Corporation Common Stock
NASDAQ:LASE
|
0.985x |
|
Sentronic International
TWO:3232
|
0.055x |
|
Next Bt Co. Ltd
KQ:065170
|
-0.031x |
|
Mindax Ltd
AU:MDX
|
-0.040x |
Annual Cash Flow Conversion Efficiency for Radiopharm Theranostics Ltd (2021–2025)
The table below shows the annual cash flow conversion efficiency of Radiopharm Theranostics Ltd from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Radiopharm Theranostics Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$42.87 Million ≈ $30.33 Million |
AU$-36.65 Million ≈ $-25.93 Million |
-0.855x | -1.76% |
| 2024-06-30 | AU$27.35 Million ≈ $19.35 Million |
AU$-22.98 Million ≈ $-16.26 Million |
-0.840x | -65.01% |
| 2023-06-30 | AU$45.58 Million ≈ $32.25 Million |
AU$-23.20 Million ≈ $-16.42 Million |
-0.509x | -223.52% |
| 2022-06-30 | AU$62.96 Million ≈ $44.55 Million |
AU$-9.91 Million ≈ $-7.01 Million |
-0.157x | -159.62% |
| 2021-06-30 | AU$-124.70K ≈ $-88.24K |
AU$-32.91K ≈ $-23.29K |
0.264x | -- |
About Radiopharm Theranostics Ltd
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more